Welcome to the Jason Carter Clinical Trials Website
Our website helps patients find clinical trials. We currently offer patient-friendly descriptions of leukemia and lymphoma trials. Early in 2018, we will be:
Adding patient-friendly trial descriptions for other blood cancers and disorders
Making improvements to the search tool
Expanding our educational resources
Didn't find a trial or need help? Contact our clinical trial specialist at 888-814-8610 or contact@ctsearchsupport.org.
A cell therapy, tabelecleucel (ATA129), to treat Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disorder (PTLD) after allogeneic (cells from a donor) blood or marrow transplant (BMT)
To find out if tabelecleucel is safe and works well to treat EBV-associated PTLD after allogeneic BMT
You may be able to join this trial if you:
Have EBV-associated PTLD after getting an allogeneic BMT
Have PTLD with CD20 markers, were treated with the drug rituximab, but the PTLD did not get better OR
Have PTLD without CD20 markers, were treated with chemotherapy (chemo), but the PTLD did not get better
Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Tabelecleucel is a cell therapy that uses T cells (a type of immune cell) from a donor. The T cells are treated in a lab so that they can find and destroy cells that are infected with EBV.
You’ll get tabelecleucel, given as an intravenous (IV) infusion 1 time each week for 3 out of every 5 weeks.
You may continue treatment for as long as the clinical trial doctors think it's best for your health. You'll have scans to see how well the treatment is working. After you finish treatment, the doctors will check your health for up to 5 years.
The Food and Drug Administration (FDA) has not yet approved tabelecleucel.
